Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2000

View Archived Issues

Array BioPharma and Lilly form drug discovery collaboration

CollaGenex seeks FDA approval for new dosage form of Periostat

Karo Bio to acquire Novalon

Significant progress reported by Genzyme Molecular Oncology for 1999

Aventis launches Arava in Canada for treatment of rheumatoid arthritis

First phase II clinical trial of ABX-IL-8 begins in psoriasis

New phosphoglycolipid useful for protecting against cardiac ischemia-reperfusion damage

Chemokine receptor modulators in early development at AstraZeneca

Helsinn initiates phase III testing of in-licensed antiemetic

Carboxylic acid PPAR modulators presented by Ono

Merck's new GABA-A receptor modulators particularly useful for Alzheimer's disease

Scios compounds useful for conditions characterized by excess p38alpha or TGF-beta activity

Merck describes preparation and use of new anticoagulants

Uprima to be considered for ED next week by FDA advisory committee

Another indication for Enbrel will be discussed at advisory committee meeting

Novel tubulin-binding antimitotic agent characterized in vitro by Abbott scientists

Celgene's IMiDs and thalidomide show activity as COX-2 inhibitors

WP-769: a doxorubicin analogue that combines oral activity and enhanced effect against topo II

Promising flavonoid discovered by Dutch investigators for preventing doxorubicin cardiotoxicity

Ro-31-7453: extensive preclinical and early clinical data presented this week to the AACR

DuPont licenses two cardiac compounds from Adenosine Therapeutics

Clinical study suggests SuperGen's Nipent effective in treating GVHD

FDA gives go-ahead for Access to commence OraDisc clinical trials

Matrix files initial section of IntraDose NDA with FDA

German researchers provide data supporting therapy with S-4718 + ciclosporin in cardiac transplants

Efficacy and mechanism of action of FR-167653 in protecting against lung I/R injury

Newly formed company to market TOBI in the Dutch market

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...